pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Siltuximab
Phase 2 · small molecule · Multicentric Castleman's Disease
Siltuximab for Multicentric Castleman's Disease is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Internal code CR016705
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen Cilag International NV
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Multicentric Castleman's Disease
- Status
- completed
- Trials
- 1